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Abstract: Background: Bleeding is a common complication of oral anticoagulation therapy.  
Objective: The present study evaluated the use of aminaphtone in patients with minor bleeding while taking warfarin.  
Methods: Seven patients suffering from bleeding of the nose and gums, who were taking therapeutic doses of warfarin, 
were included in the study.  
Results: The patients were prescribed 75 mg aminaphtone twice daily. For 5 of these patients the bleeding was controlled 
within 48 h, for 1, within 96 h and for the other, a satisfactory reduction was obtained.  
Conclusion: Patients with minor bleeding during treatment using oral anticoagulation, who are free from risk of other 
complications, can benefit from the use of aminaphtone as an initial therapeutic option. 
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INTRODUCTION 
  Bleeding is the most important complication of oral anti-
coagulation, with the risks being reduced when the interna-
tional normalized relation (INR) is maintained within the 
therapeutic range (between 2 and 3) [1, 2]. Excessive bleed-
ing can be life threatening. Therefore, tight control of coagu-
lation is essential. Minor bleeding does not expose patients 
to any major risk [1, 2], but is distressing. 
  Oral warfarin, the basis of preventive anticoagulation 
therapy, is a vitamin K antagonist requiring careful monitor-
ing as it produces side effects and drug-induced interactions. 
Despite of the evident efficacy, there are risks and its indica-
tion is based on probable benefits [3]. Epistaxis is the most 
common bleeding because of the extensive vascularization, 
the fragility of the nasal mucosa and the exposure of the area 
to trauma and irritant agents. Generally bleeding is minor 
[4]. 
  We evaluated the use of aminaphtone to abate minor 
bleeding in patients on warfarin. 
CASE REPORT 
   Seven patients on warfarin for deep venous thrombosis 
who presented with bleeding were evaluated in a prospec-
tive, quasi-randomized, for order of arrival in observational 
study. Inclusion criteria were the presence of minor bleeding 
at easily accessible locations and an INR between 2.0   
and 3.5. Exclusion criteria included more severe bleeding,  
an INR outside the standard therapeutic range and locations  
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that were difficult to access (e.g. the gastrointestinal tract). 
All patients presented with 2 or more episodes of bleeding 
per day for more than 3 days prior to the consultation. Com-
plete blood tests and coagulograms (INR- relation normal-
ized international) were performed on the day of the consul-
tation and after 8 days. Patients were administered 75 mg 
aminaphtone 2 times daily and were requested to monitor 
bleeding; in cases of more severe bleeding they were advised 
to return immediately to the clinic. 
RESULTS 
  Four of the 7 patients were men; ages ranged between 47 
and 71 years old. For 5 patients the bleeding was controlled 
within 48 h and for another patient, within 96 h. The final 
patient suffering from bleeding gums presented with an im-
provement; however bleeding did not stop completely. The 
bleeding in this case occurred after brushing teeth. After ini-
tiating treatment with aminaphtone the patient reported that 
the bleeding was less with episodes every 2 or 3 days. The 
patient’s progress was monitored for 1 month without the 
drug interfering in the anticoagulation. After the first week, 
the INR remained within the therapeutic range. 
DISCUSSION 
  The current study shows improvements in the bleeding of 
nose and gums of patients on anticoagulation. Despite the 
small number of participants, this study opens a new possi-
bility of treating selected cases of patients suffering from 
minor bleeding but without anemia or evident risk of other 
complications. Doubts related to the effect on the levels of 
anticoagulation, even when they are within the therapeutic 
range, are commonly experienced in daily practice. The hy-
pothesis is that these patients present alterations in capillary Aminaphtone Under Oral Anticoagulation  The Open Cardiovascular Medicine Journal, 2010, Volume 4    147 
fragility, and so aminaphtone improves the fragility thereby 
treating the cause of bleeding. Most cases of gum bleeding 
result from self-inflicted injuries, generally during oral hy-
giene and specifically due to too vigorous brushing of teeth 
or toothbrushes with very hard bristles. 
    Aminaphtone is a bioflavonoid that increases capillary 
resistance by the inhibition of hyaluronidases [5]. There are 
few published reports related to this approach, however there 
are case reports showing significant improvements in spon-
taneous and chronic epistasis in 2 patients [6, 7]. The blood 
losses occurring during multiple dental extractions under 
general anesthesia in pretreated patients have been measured. 
The results obtained have been processed statistically and 
confirm the effectiveness of the product [8]. The case report 
describes control of Schamberg's disease using aminaphtone 
[9]. A preliminary in vitro study suggested that aminaphtone, 
a naphthohydrochinon used in the treatment of capillary dis-
orders, may downregulate the expression of adhesion mole-
cules in endothelial cells. In a pilot study of a select group of 
patients with systemic sclerosis, aminaphtone was associated 
with the downregulation of sELAM-1 and sVCAM-1 con-
centrations [10]. 
  These findings reinforce the necessity of additional re-
search involving multicentre studies aiming at confirming 
possible mechanisms of action of these drugs. 
   Minor bleeding in patients on oral anticoagulants, with-
out risk of more severe complications, may benefit from the 
use of aminaphtone as an initial therapeutic option. 
  However, few clinical studies evaluating this drug. There 
is a need to better assess the interactions with other drugs 
such as anticoagulants. 
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